Dislipidemia and systemic inflammation in HIV-infected patients against combined antiretroviral therapy.

V. A. Vasylenko

Abstract


There were screened 142 HIV-infected patients receiving combined antiretroviral therapy (сART) for at least 6 months and who reached a level of viral load (HIV-RNA) less than 50 copies/ml and without  clinical manifestations of cardiovascular disease. The study did not include patients with acute inflammation, the number of CD4 + T lymphocytes less than 200 cells/ml, patients with drug addiction and alcoholism. The aim of the study was to establish the severity of dyslipidemia and systemic inflammation in HIV-infected patients, depending on the level of CD4 + T-lymphocytes. It has been established that among patients with HIV receiving сART for a long time, a highly aterogeneic dyslipidemia IIb according to the classification D. Fredrickson develops. Negative prognosis for the course of atherosclerosis in this category of patients is confirmed by a high concentration of С-reactive protein (CRP). An effective сART promotes the reduction of levels of total cholesterol, triglycerides and atherogenicity index against the background of increased high density lipoproteins. At the same time, the concentration of low density lipoproteins does not change and the level of CRP does not decrease sufficiently, which indicates to an unfavorable prognosis for the risk of atherosclerosis progression and cardiovascular complications in HIV-infected patients.

Keywords


HIV-infection; CD4+ T-lymphocytes; high-sensitivity C-reactive protein; lipidogram

References


Zhukova VA, Shalnova SA,MetelskayaVA.[C-reactive protein: the current state of the problem]. Kardio­vaskulyarnaya terapiya i profilaktika. 2011;1:90-95. Russian.

Lutai MI. [Atherosclerosis: a modern view of pa­thogenesis]. Ukrainsky kardiologіchny Journal. 2004;1:22-34. Russian.

D’Ascenzo F, Cerrato E, Calcagno A, et al. High pre­valence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015;240:197-204.

Koening W, Frohlich M, et al. C-reactive protein a sensitive marker of inflammation, predict future risk of coronary heart diseasein initially healthy middle-aged men. Results from MONICA (Monitoring Trends and De­terminants in Cardiovascular Disease) Ausburg Cohort study, 1984 to1992. Circulation. 1999;99:237-42.

Chetty R, Batitang S, Nair R. Large artery vascu­lopathy in HIV-positive patients: another vasculitic enig­ma. Hum Pathol. 2000;31:374-9.

Lang S, Boccara F, Mary-Krause M, et al. Epide­miology of coronary heart disease in HIVinfected versus uninfected individuals in developed countries. Arch Cardiovasc Dis. 2015;108:206-15.

Estrada V, Portilla J. Dyslipidemia related to anti­retroviral therapy. AIDS Rev. 2011;13:49-56.

Haverkate F, Thompson S, Pyke S. Production of C-reactive protein and risk of coronary events in stable and unstable angina. Lancet. 1997;349:462-6.

Vachiat А, McCutcheon К, Tsabedze N, et al. HIV and Ischemic Heart Disease J Am Coll Cardiol 2017;69(1):73-82.

Hulten E, Mitchell J, Scally J, et al. HIV posi­tivity, protease inhibitor exposure and subclinical athe­rosclerosis: a systematic review and meta-analysis of observational studies. Heart 2009;95:1826-35.

TriantVA, Lee H, Hadigan C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human im­munodeficiency virus disease. J Clin Endocrinol Metab. 2007;92:2506-12.

Kuller LH, Tracy RP, Shaten J. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996;144:537-47.

Mendall MA, Strachan DP. C-reactive protein: re­lation to total mortality, cardiovascular risk factors for men. Eur Heart J. 2001;21:2584-90.

Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk. JACC. 2007;49:2129-38.

Robbs JV, Paruk N. Management of HIV vascu­lopathy: a South African experience. Eur J Vasc Endo­vasc Surg. 2010;39 Suppl 1:25-31.

Tseng ZH, Secemsky EA, Dowdy D, et al. Sud­den cardiac death in patients with human immuno­de­fi­ciency virus infection. J Am Coll Cardiol 2012;59:1891-6.


GOST Style Citations


  1. Жукова В.А. С-реактивный белок: современ­ное состояние проблемы / В.А. Жукова, С.А. Шаль­нова, В.А. Метельская // Кардиоваскулярная терапия и профилактика. – 2011. – № 1. – С. 90–95.
  2. Лутай М.И. Атеросклероз: современный взгляд на патогенез / М.И. Лутай // Укр. кардіол. жур­нал. – 2004. – № 1. – C. 22-34.
  3. High prevalence at computed coro­nary tomo­graphy of non-calcified plaques in asymp­tomatic HIV patients treated with HAART: a meta-analysis / F. D’As­cenzo, E. Cerrato, A. Calcagno [et al.] // Atherosclerosis. – 2015. – Vol. 240. – P. 197–204.
  4. C-reactive protein a sensitive marker of in­flammation, predict future risk of coronary heart diseasein initially healthy middle-aged men. Results from MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Ausburg Cohort study, 1984 to 1992 / W. Koening, M. Sund, M. Frohlich [et al] // Cir­culation. – 1999. – Vol. 99. – P. 237–242.
  5. Chetty R. Large artery vasculopathy in HIV-po­sitive patients: another vasculitic enigma / R. Chetty,S. Batitang, R. Nair // Hum. Pathol. – 2000. – Vol. 31. – P. 374-379.
  6. Epidemiology of coronary heart disease in HIV infected versus uninfected individuals in developed coun­tries / S. Lang, F. Boccara, M. Mary-Krause [et al.] // Arch. Cardiovasc. Dis. – 2015. – Vol. 108. – P. 206–215.
  7. Estrada V. Dyslipidemia related to antiretroviral therapy / V. Estrada, J. Portilla // AIDS Rev. – 2011. – Vol. 13. – P. 49–56.
  8. Haverkate F. Production of C-reactive protein and risk of coronary events in stable and unstable angina / F. Haverkate, S. Thompson,S. Pyke// Lancet. – 1997. – Vol. 349. – P. 462–466.
  9. HIV and Ischemic Heart Disease / А. Vachiat, К. McCutcheon, N. Tsabedze [et al.] / J. Am. Coll. Cardiol. – 2017. – Vol. 69, N 1. – P. 73-82.
  10. HIV positivity, protease inhibitor exposure and subclinical atherosclerosis: a systematic review and meta-analysis of observational studies /E. Hulten, J. Mitchell, J. Scally [et al.] // Heart. – 2009. – Vol. 95. – P. 1826–1835.
  11. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease / V.A. Triant, H. Lee, C. Hadigan [et al.] // J. Clin. Endocrinol. Metab. – 2007. – Vol. 92. – P. 2506–2512.
  12. Kuller L. H. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study / L. H. Kuller, R.  P. Tracy, J. Shaten // Am. J. Epi­demiol. – 1996. – Vol. 144. – P. 537–547.
  13. Mendall М.A. C-reactive protein: relation to total mortality, cardiovascular risk factors for men / M.A. Mendall, D.P. Strachan // Eur. Heart J. – 2001. – Vol. 21. – P. 2584-2590.
  14. Ridker P.M. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk / P.M. Ridker // JACC. – 2007. – Vol. 49. – P. 2129-2138.
  15. Robbs J.V. Management of HIV vasculopathy: a South African experience / J.V. Robbs,N. Paruk// Eur. J. Vasc. Endovasc. Surg. – 2010. – Vol. 39, N 1. – P. 25-31.
  16. Sudden cardiac death in patients with human im­munodeficiency virus infection / Z.H. Tseng, E.A. Se­cemsky, D. Dowdy [et al.] // J. Am. Coll. Cardiol. – 2012. – Vol. 59. – P. 1891-1896.




DOI: https://doi.org/10.26641/2307-0404.2018.1(part1).127203